ClinConnect ClinConnect Logo
Search / Trial NCT05728840

Virtual-reality Exercises for Alleviating Attention Deficits in Patients with Acquired Brain Injury

Launched by MINDMAZE SA · Feb 14, 2023

Trial Information

Current as of August 21, 2025

Recruiting

Keywords

Stroke Attention Executive Functions Virtual Reality Neurorehabilitation

ClinConnect Summary

This clinical trial is studying the use of virtual reality exercises to help improve attention and focus in patients who have experienced brain injuries, such as strokes. Attention problems are common after a stroke, affecting many survivors and making daily tasks challenging. The goal of the study is to see if fun, game-like exercises in a virtual reality setting can help patients regain their attention skills better than traditional exercises.

To be eligible for the trial, participants must be at least 18 years old and have had a stroke within the past month. They also need to show that they have difficulty with attention based on specific tests. However, individuals with certain conditions, like epilepsy or severe memory issues, cannot participate. If accepted, participants can expect to engage in interactive, gamified training sessions that aim to enhance their cognitive abilities in a supportive environment. This study is currently recruiting participants of all genders and aims to provide valuable insights into new ways to support recovery after brain injuries.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Time from stroke onset \< 1 month
  • Objective pathological performance on at least one standardized test or subtest on attention during standard neuropsychological evaluation
  • Brain injury documented by routine neuroradiological examination (computed tomography or magnetic resonance imaging scan)
  • Able to give informed consent as documented by signature
  • Age \>= 18 years old
  • Exclusion Criteria:
  • Epilepsy
  • Inability or contraindications to undergo the investigated intervention
  • Major psychiatric co-morbidity
  • Major neurocognitive deficits (e.g. dementia)
  • Incapacity to discriminate colors
  • General cognitive state preventing to understand and perform the tasks
  • Decision to not be informed of incidental findings

About Mindmaze Sa

MindMaze SA is a pioneering neurotechnology company dedicated to transforming the way neurological disorders are diagnosed and treated. By integrating advanced virtual reality, motion capture, and artificial intelligence, MindMaze develops innovative therapeutic solutions that enhance patient outcomes in rehabilitation and cognitive health. With a strong commitment to research and development, the company collaborates with leading academic institutions and healthcare providers to advance clinical trials and bring cutting-edge therapies to market, ultimately improving the quality of life for individuals affected by neurological conditions.

Locations

Lausanne, , Switzerland

Patients applied

0 patients applied

Trial Officials

Sonia Crottaz-Herbette

Principal Investigator

University of Lausanne Hospitals

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials